Prevail Therapeutics to Present at Upcoming October Conferences
October 01 2019 - 4:05PM
Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the
Company”), a biotechnology company developing potentially
disease-modifying AAV-based gene therapies for patients with
neurodegenerative disorders, today announced that management will
present at three upcoming conferences in October:
- 2019 Cell & Gene Meeting on the Mesa on
Thursday, October 3, 2019 at 12:00 p.m. PT in Carlsbad, CA.
- Chardan’s Annual Genetic Medicines Conference
on Tuesday, October 8, 2019 at 9:00 a.m. ET in New York, NY.
- 2019 Jefferies Gene Editing Summit on Tuesday,
October 8, 2019 at 1:10 p.m. ET in New York, NY.
The live webcast of all conferences will be available in the
investor section of the company's website at
www.prevailtherapeutics.com. The webcast will be archived for 90
days following the presentation.
About Prevail Therapeutics Prevail is a gene
therapy company leveraging breakthroughs in human genetics with the
goal of developing and commercializing disease-modifying AAV-based
gene therapies for patients with neurodegenerative diseases.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a
collaborative effort with The Silverstein Foundation for
Parkinson’s with GBA and OrbiMed, and is headquartered in New York,
NY.
Media Contact:Katie Engleman1AB
katie@1ABmedia.com
Investor
Contact:investors@prevailtherapeutics.com
Prevail Therapeutics (NASDAQ:PRVL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prevail Therapeutics (NASDAQ:PRVL)
Historical Stock Chart
From Apr 2023 to Apr 2024